This document is an excerpt from the EUR-Lex website
Document 62024CN0181
Case C-181/24, Genmab: Request for a preliminary ruling from the Fővárosi Törvényszék (Hungary) lodged on 6 March 2024 - Genmab A/S
Case C-181/24, Genmab: Request for a preliminary ruling from the Fővárosi Törvényszék (Hungary) lodged on 6 March 2024 - Genmab A/S
Case C-181/24, Genmab: Request for a preliminary ruling from the Fővárosi Törvényszék (Hungary) lodged on 6 March 2024 - Genmab A/S
OJ C, C/2024/3059, 13.5.2024, ELI: http://data.europa.eu/eli/C/2024/3059/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
![]() |
Official Journal |
EN C series |
C/2024/3059 |
13.5.2024 |
Request for a preliminary ruling from the Fővárosi Törvényszék (Hungary) lodged on 6 March 2024 - Genmab A/S
(Case C-181/24, Genmab)
(C/2024/3059)
Language of the case: Hungarian
Referring court
Fővárosi Törvényszék
Parties to the main proceedings
Applicant: Genmab A/S
Other party: Szellemi Tulajdon Nemzeti Hivatala
Question referred
Must Article 3(b) and (d) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (1) be interpreted as meaning that a marketing authorisation predating the marketing authorisation appearing in the application for a supplementary protection certificate and referring to the same product must be regarded as the first marketing authorisation for the purposes of that regulation, even where that prior marketing authorisation was withdrawn prior to the submission of the application for the certificate?
ELI: http://data.europa.eu/eli/C/2024/3059/oj
ISSN 1977-091X (electronic edition)